Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.

Christof Kazda Jennifer LeohrRong LiuShobha ReddyMary Anne DellvaMei Teng LohThomas HardyLeona Plum-Mörschel

Published in: Diabetes, obesity & metabolism (2021)

URLi showed accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T1D.

Keyphrases

blood glucose
glycemic control
double blind
placebo controlled
type diabetes
clinical trial
open label
blood pressure
high resolution
study protocol
randomized controlled trial
phase iii
metabolic syndrome
weight loss
loop mediated isothermal amplification
sensitive detection